1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Univariable ANOVA of clinical variables as predictors of platelet inhibition
Platelet Inhibition (%)Parameter Estimate (b)P Value
Demographics
    Age (years)–−0.25.303
    Age groups (No.)−15.8.031
        <55 years (21)53.0
        >55 years (34)37.2
    Sex (No.)−2.3.755
        Women (34)44.1
        Men (21)41.8
Medical history
    Hypertension (No.)−13.1.077
        No (34)48.2
        Yes (21)35.1
    Diabetes (No.)−24.0.036
        No (49)45.8
        Yes (6)21.8
    Hypercholesterolemia (No.)−11.8.153
        No (41)46.2
        Yes (14)34.4
    Coronary artery disease (No.)2.7.789
        No (47)43.6
        Yes (8)40.9
    Prior stroke (No.)6.7.414
        No (40)41.4
        Yes (15)48.1
    Prior TIA (No.)−11.6.288
        No (48)44.7
        Yes (7)33.1
    Statin use (No.)−13.9.085
        No (40)47.0
        Yes (15)33.1
    ACE-I use (No.)−13.5.199
        No (48)45.0
        Yes (7)31.5
    Beta blocker use (No.)−4.0.684
        No (46)43.9
        Yes (9)39.9
    Ca-channel blocker use (No.)6.9.671
        No (52)42.8
        Yes (3)49.7
    Diuretic use (No.)−5.1.471
        No (49)44.1
        Yes (6)35.7
    Aspirin use (No.)−8.4.562
        No (3)52.0
        Yes (52)47.7
    Timing of clopidogrel initiation (No.)−0.8.889
        <3 days (14)43.2
        3–7 days (25)44.9
        >7 days (16)40.7
Laboratory values
    Creatinine (mg/dL)–−22.7.175
    Glucose (mg/dL)–−0.21.035
    Hemoglobin (g/dL)–−0.55.825
    Platelet count (1,000/μL)–0.07.190
Angiographic features
    Stent indication (No.)−6.0.490
        Aneurysm (42)45.1
        Stenosis (13)39.1
    Stent location (No.)−14.7.029
        MCA/ACA/PcomA (19)53.4
        Other (36)38.7
Outcomes
    Re-stenosis at 6 months (No.)7.8.774
        No (54)43.1
        Yes (1)50.9
    Stroke or TIA at 6 months (No.)−4.8.806
        No (53)43.4
        Yes (2)38.6
  • Note:— –indicates data not available; TIA, transient ischemic attack; Ca, calcium; MCA, middle cerebral artery; ACA, anterior cerebral artery; PcomA, posterior communicating artery; No., number.